Datapoint: CVS Returns Eliquis to Preferred Formulary

Following an outcry over safety concerns, CVS will return Bristol Myers Squibb and Pfizer’s Eliquis to its national preferred formulary July 1, according to reporting from Modern Healthcare. The blood thinner was removed in January, with patients advised to switch to Johnson & Johnson’s Xarelto. This sparked pushback from providers, however, as abruptly switching blood thinners can pose health risks to patients. 90% of all insured lives currently have preferred access to Eliquis under the pharmacy benefit, to Xarelto’s 99%.

SOURCE: MMIT Analytics, as of 6/27/22

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
August 17

Datapoint: Humana Inks Deal to Acquire Inclusa

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
August 16

Datapoint: Mississippi Unveils Medicaid Contract Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
August 15

Datapoint: SCAN Plots MA Expansion Into Texas

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today